Biotech News — fda

fda MDGL

Madrigal's Rezdiffra (Resmetirom): The First MASH Drug Is Already on the Market

The FDA approved Madrigal's resmetirom (Rezdiffra) on March 14, 2024 — the first-ever drug for MASH/NASH. Now the focus shifts to launch execution and label expansion.

July 22, 2026 · Rare Disease · $MDGL

fda CRSP

CRISPR Therapeutics' Zugo-cel (CTX112): Next-Gen CAR-T Advances in Phase 1/2

CRISPR Therapeutics' CTX112 — renamed zugocabtagene geleucel (zugo-cel) — is a next-gen allogeneic CAR-T for B-cell malignancies and autoimmune diseases. Phase 1/2 data is promising, but no BLA has been filed.

July 18, 2026 · Gene Therapy · $CRSP